- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05925218
Circulating Tumor DNA Collection From Patients With High Grade Gliomas (m-ctDNA)
December 21, 2023 updated by: University Health Network, Toronto
Improved outcomes for high-grade gliomas (HGG) require advances in our ability to monitor changes to tumour biology using non-surgical approaches.
"Liquid biopsy" is a term used to describe a technique whereby tumour DNA, which has been shed off and then circulates through the blood stream, is detected and analyzed.
Our goal is to develop a new type of liquid biopsy that is suitable for primary brain tumours that uses a method that is highly sensitive and allows for ongoing analysis of these tumours.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study objective is to determine the feasibility of measuring both the burden and key molecular features of HGG through profiling of plasma circulating tumour DNA (ctDNA).
This will be determined by detecting ctDNA in samples from HGG patients, and measuring changes in ctDNA levels over time following HGG treatment.
50 eligible patients will be enrolled in the study at University Health Network, and up to 10 blood samples will be obtained; up to 2 blood samples prior to their radiotherapy treatment, and 8 blood samples after their radiotherapy treatment.
If available, tissue samples that are stored at UHN will also be collected for DNA extraction.
Study Type
Observational
Enrollment (Estimated)
70
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, L4W4C2
- Recruiting
- University Health Network
-
Contact:
- David Shultz, MD
- Phone Number: 6899 416 946 4501
- Email: david.shultz@rmp.uhn.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with suspected or pathologically-proven, previously untreated high grade gliomas
Description
Inclusion Criteria:
- Patients can be enrolled either prior to a planned surgery/biopsy for a suspected HGG or after biopsy/surgery of pathologically proven, previously untreated HGG, prior to adjuvant radiotherapy
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
- Age ≥18 yrs
Exclusion Criteria:
- History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of measuring both the burden and key molecular features of high- grade gliomas (HGG) through profiling of plasma circulating tumour DNA (ctDNA)
Time Frame: 2 years
|
Feasibility in this context will be defined by 1) detecting ctDNA in samples from HGG patients and 2) measuring changes in levels of specific ctDNA fragments following HGG treatment
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 2, 2022
Primary Completion (Estimated)
September 30, 2024
Study Completion (Estimated)
September 30, 2024
Study Registration Dates
First Submitted
June 21, 2023
First Submitted That Met QC Criteria
June 21, 2023
First Posted (Actual)
June 29, 2023
Study Record Updates
Last Update Posted (Actual)
December 26, 2023
Last Update Submitted That Met QC Criteria
December 21, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-5047
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No plan to share.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High Grade Glioma
-
James FelkerConnor's Cure; Ellie Kavalieros Fund; Translational Brain Tumor Research FundActive, not recruitingNewly Diagnosed Pediatric Pontine Glioma | Newly Diagnosed Pediatric High Grade Glioma | Recurrent Pediatric High Grade Glioma | Recurrent Pediatric Low Grade GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Maastricht Radiation OncologyMaastricht University Medical Center; Ziekenhuis Oost-Limburg; Zuyderland Medisch...Active, not recruitingHigh Grade Glioma | Low-grade GliomaNetherlands
-
The University of Texas Health Science Center at...CompletedHIGH GRADE GLIOMAUnited States
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Hospices Civils de LyonCompletedLow Grade Glioma (LGG) | High Grade Glioma (HGG)France
-
Hospices Civils de LyonTerminatedLow Grade Glioma (LGG), High Grade Glioma (HGG)France
-
University of California, San FranciscoNovartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...RecruitingHigh Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
BioMimetix JV, LLCNational Cancer Institute (NCI); Duke Cancer InstituteActive, not recruitingGlioblastoma | High Grade Glioma | Astrocytoma, Grade IIIUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); Treovir, LLC; American Lebanese Syrian Associated...Not yet recruitingNeoplasms | Malignant Glioma of Brain | Glioblastoma Multiforme | High Grade Glioma | Giant Cell Glioblastoma | High-grade Glioma | Anaplastic Astrocytoma of Brain | Anaplastic GliomaUnited States
Clinical Trials on Radiotherapy as per standard of care
-
iOMEDICO AGRecruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction AdenocarcinomaGermany
-
iOMEDICO AGDeutsche Studiengruppe Multiples Myelom (DSMM)Recruiting
-
iOMEDICO AGRecruitingChronic Lymphocytic Leukemia (CLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL) | Waldenström's Macroglobulinemia (WM)Germany
-
iOMEDICO AGRecruiting
-
Unity Health TorontoRoche Pharma AGCompletedDyspnea | Acute Heart Failure | Shortness of BreathCanada, United States, New Zealand
-
Samir SabaCompletedHeart Failure, Wide QRS ComplexUnited States
-
Institut BergoniéFrench Sarcoma GroupActive, not recruitingMetastatic Bone TumorFrance
-
Cadila PharnmaceuticalsCouncil of Scientific and Industrial Research, IndiaCompleted
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityCompletedPeriodontitis | Gingivitis | Dental HygienePakistan
-
University of Maryland, BaltimoreRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Oropharynx Squamous Cell CarcinomaUnited States